It shows that the presence and/or rapid recall of pertussis antibodies are crucial to protection and that TLR9 (better than TLR4 agonists) may improve current aP vaccines and thus possibly better protect adolescents and adults against pertussis. Here, TLR4 is linked to pertussis.